Cancer treatments have evolved, improving survival rates and quality of life, challenging the notion of cancer as a death ...

Ivonescimab combined with chemotherapy significantly improved progression-free survival (PFS) compared with Tevimbra ...

The addition of tiragolumab to Tecentriq and Avastin did not significantly improve progression-free survival in ...

The DUO-O trial showed significant improvement in progression-free survival with Imfinzi, Avastin, and Lynparza, but no ...

Trodelvy reduced progression or death risk by 51% compared to chemotherapy in EGFR-mutated non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors. The median progression-free survival ...

Adding Xtandi to androgen deprivation therapy and radiation did not significantly improve metastasis-free survival in high-risk localized prostate cancer.

Loqtorzi significantly improved progression-free and overall survival in HER2-expressing advanced urothelial carcinoma compared to chemotherapy. The study demonstrated a higher overall response rate ...

Neoadjuvant Enhertu then THP improved pathological complete response rate in patients with high-risk, HER2-positive early ...

Sacituzumab tirumotecan (sac-TMT) significantly improved progression-free survival compared to chemotherapy in HR-positive, ...

Enhertu significantly improved IDFS compared to Kadcyla, with a 53% risk reduction in invasive disease or death in high-risk, ...